Inotiv Financials
Inotiv Inc. acquired Envigo in November 2021, gaining its Research Models and Services (RMS) segment. RMS revenue declined from $387M (22.8% margin) in FY2023 to $311M (14.2%) in FY2024 before recovering to $325M (17.4%) in FY2025. One client accounts for 16.6% of RMS revenue. Inotiv has operated at a consolidated loss despite positive RMS margins, burdened by $35M+ in Envigo-related penalties. The RMS segment includes rodents, rabbits, NHPs, and services — it is not a pure beagle margin.
Overview
Inotiv Inc. is a publicly traded contract research organization and research model supplier. The company acquired Envigo in November 2021, a deal that brought both a large-scale animal breeding operation and, eventually, the largest Animal Welfare Act penalty in history.
The Envigo Acquisition
The Envigo acquisition was intended to create a vertically integrated preclinical services company — breeding animals and conducting the studies that use them. Instead, the Cumberland, Virginia facility became the subject of federal enforcement action within months. The resulting $35 million+ in penalties, legal costs, and remediation expenses transformed the acquisition from a growth strategy into a financial burden.
RMS Segment Performance
Inotiv's Research Models and Services (RMS) segment — the unit that includes the former Envigo operations — shows a trajectory of decline and partial recovery.
- FY2023 — Revenue: $387M, operating margin: 22.8%
- FY2024 — Revenue: $311M, operating margin: 14.2%
- FY2025 — Revenue: $325M, operating margin: 17.4%
The revenue decline from FY2023 to FY2024 reflects the loss of the Cumberland facility, reputational damage, and broader market softness in preclinical services.
Customer Concentration
A single client accounted for 16.6% of RMS segment revenue in FY2025. This level of customer concentration creates material risk — the loss of that relationship would significantly impact segment economics. Inotiv does not publicly identify the client.
Consolidated Performance
Despite positive RMS margins, Inotiv has operated at a consolidated loss. The company carries debt from the Envigo acquisition, penalties from the enforcement action, and overhead from its Discovery and Analytical Services segment. The stock price crashed following the Envigo case and has not recovered to pre-crisis levels.
What RMS Actually Includes
The RMS segment is not a beagle business. It includes:
- Rodents — Rats and mice, the highest-volume research models
- Rabbits
- Non-human primates (NHPs)
- Dogs — Including but not limited to beagles
- Services — Housing, breeding, genetic testing, health monitoring
Isolating a "beagle margin" from public filings is not possible. Dog revenue is a subset of a segment that generates revenue from multiple species and service lines. Anyone citing Inotiv margins as evidence of beagle-specific profitability is extrapolating beyond what the data supports.
Significance
Inotiv's financial trajectory illustrates the risk profile of the research model supply business. The Envigo acquisition showed how quickly regulatory failure can transform a profitable segment into a liability. It also demonstrated that the beagle trade's economics are embedded in diversified corporate structures where dog breeding is one component among many.
Sources
- 1.Inotiv SEC Filings, FY2023-FY2025. 10-K annual reports with segment-level financial data.
- 2.Inotiv Annual Reports, various. Management discussion and analysis of RMS segment performance.